The aim is to assess the effectiveness of denosumab in treating aggressive benign bone lesions in children.
Data from clinical cases analyzed for the treatment of aggressive benign bone lesions.
Denosumab administered as a therapeutic intervention with follow-up evaluations for outcomes.
No specific numerical results or findings provided in the abstract.
Abstract
The authors have nothing to report. The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.